M&A Deal Summary

Q² Solutions Acquires Nexelis

On January 10, 2022, Q² Solutions acquired life science company Nexelis from Ampersand Capital Partners

Acquisition Highlights
  • This is Q² Solutions’ 2nd transaction in the Life Science sector.
  • This is Q² Solutions’ 1st transaction in Canada.
  • This is Q² Solutions’ 1st transaction in Quebec.

M&A Deal Summary
Date 2022-01-10
Target Nexelis
Sector Life Science
Buyer(s) Q² Solutions
Sellers(s) Ampersand Capital Partners
Deal Type Add-on Acquisition

Target

Nexelis

Laval, Quebec, Canada
Nexelis is an immunology-centric CRO specialized in preclinical models and clinical assay development in single and multiplex formats and sample analysis for low-, mid- and large-scale clinical testing. the company's team of scientists and technology platforms have been instrumental in the development, qualification, and validation of assays supporting FDA filings of over 100 new molecular entities, including blockbuster biologics such as vaccines and complex large molecules.

Search 201,771 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Q² Solutions

Morrisville, North Carolina, United States
Category Company
Founded 2015
Sector Life Science
DESCRIPTION

Q² Solutions is a global clinical trial laboratory services organization that helps biopharmaceutical, medical device, and diagnostics customers improve human health through innovation that transforms science and data into actionable medical insights. Q² Solutions is a quality-driven, responsive partner with strong global experience and deep scientific and medical expertise. Q² Solutions was formed in 2015 and is based in Morrisville, North Carolina.

DEAL STATS #
Overall 2 of 2
Sector (Life Science) 2 of 2
Type (Add-on Acquisition) 1 of 1
State (Quebec) 1 of 1
Country (Canada) 1 of 1
Year (2022) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-05-24 Myriad RBM

Austin, Texas, United States

Myriad RBM is a multiplexed immunoassay testing laboratory that solves complex drug development challenges with innovative biomarker services and a novel whole blood immunophenotyping device (TruCulture®). Myriad RBM was founded in 2002 and is based in Austin, Texas.

Buy -

Seller(S) 1

SELLER

Ampersand Capital Partners

Wellesley, Massachusetts, United States

Investor Investor Investor Investor Investor

Category Growth Capital Firm
Founded 1988
PE ASSETS 3.0B USD
Size Large
Type Sector Focused
DESCRIPTION

Ampersand Capital Partners is a middle-market private equity group that concentrates on growth equity investment opportunities in the healthcare sector. The Firm looks to invest $10 to $100 million in businesses with $10 to $100 million of revenue. Specific areas of interests within healthcare include lab products, specialty diagnostic equipment, pharmaceutical outsourcing, and specialty pharma. Ampersand generally prefers to be the first and sole institutional investor. Ampersand was formed in 1988 and is based in Wellesley, Massachusetts.

DEAL STATS #
Overall 48 of 55
Sector (Life Science) 20 of 25
Type (Add-on Acquisition) 34 of 38
State (Quebec) 1 of 1
Country (Canada) 1 of 1
Year (2022) 1 of 7
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-01-07 AnaBios

San Diego, California, United States

AnaBios is a preclinical contract research organization (CRO) that focuses on translational research with unique capabilities to measure drug activity directly in human tissue. AnaBios is based in San Diego, California.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-01-20 Kedrion

Lucca, Italy

Kedrion is engaged in development, manufacture, and distribution of a broad range of protein products derived from human plasma. Kedrion was founded in 2001 and is based in Lucca, Italy.

Buy -
Mergr

Product

Company

Legal